StreetInsider.com News Articles

Wolfe Research Upgrades uniQure BV (QURE) to Outperform

Wed, 29 Jul 2026 16:19:39 -0400

Wolfe Research analyst Rudy Li upgraded uniQure BV (NASDAQ: QURE) from Peerperform to Outperform with a price target of $65.00.

The analyst comments "The stock has priced in <50% POS for approval amid concerns stemming from the recent AdComs, but in our view, QURE has a stronger case than the market appreciates. We model 70% POS and $2B US peak sales for AMT-130, upgrading to OP with $65 PT."

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $36.66 yesterday.

Wolfe Research Upgrades uniQure BV (QURE) to Outperform

Wed, 29 Jul 2026 16:19:39 -0400

Wolfe Research analyst Rudy Li upgraded uniQure BV (NASDAQ: QURE) from Peerperform to Outperform with a price target of $65.00.

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $36.66 yesterday.

uniQure (QURE) Misses Q2 EPS by 38c

Wed, 29 Jul 2026 07:30:37 -0400

uniQure (NASDAQ: QURE) reported Q2 EPS of ($1.22), $0.38 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $5.84 million versus the consensus estimate of $5.49 million.

For earnings history and earnings-related data on uniQure (QURE) click here.

Form S-8 uniQure N.V.

Wed, 29 Jul 2026 07:29:00 -0400

si-local-file:///var/storage/secattach/20260729/26830596.html

Form S-8 uniQure N.V.

Wed, 29 Jul 2026 07:29:00 -0400

si-local-file:///var/storage/secattach/20260729/26830596.html

Form 10-Q uniQure N.V. For: Jun 30

Wed, 29 Jul 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260729/26830548.html

Form 10-Q uniQure N.V. For: Jun 30

Wed, 29 Jul 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260729/26830548.html

Form 8-K uniQure N.V. For: Jul 29

Wed, 29 Jul 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260729/26830463.html

Form 8-K uniQure N.V. For: Jul 29

Wed, 29 Jul 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260729/26830463.html

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Wed, 29 Jul 2026 07:05:00 -0400

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~

~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~

~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~

~ Strengthened financial position with $259 million follow-on offering, extending cash runway into 2030 and funding the anticipated commercial launch of AMT-130

uniQure to Announce Second Quarter 2026 Financial Results

Wed, 22 Jul 2026 07:05:00 -0400

LEXINGTON, Mass. and AMSTERDAM, July 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Management will then host a conference call at 8:30 a.m. ET.

The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in

uniQure to Announce Second Quarter 2026 Financial Results

Wed, 22 Jul 2026 07:05:00 -0400

LEXINGTON, Mass. and AMSTERDAM, July 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Management will then host a conference call at 8:30 a.m. ET.

The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in

uniQure to Announce Second Quarter 2026 Financial Results

Wed, 22 Jul 2026 07:05:00 -0400

LEXINGTON, Mass. and AMSTERDAM, July 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Management will then host a conference call at 8:30 a.m. ET.

The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in

uniQure to Announce Second Quarter 2026 Financial Results

Wed, 22 Jul 2026 07:05:00 -0400

LEXINGTON, Mass. and AMSTERDAM, July 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Management will then host a conference call at 8:30 a.m. ET.

The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in